Stem Cells http://www.stemcellsportal.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kabarowski, J. H. S.
Right arrow Articles by Witte, O. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kabarowski, J. H. S.
Right arrow Articles by Witte, O. N.
Stem Cells, Vol. 18, No. 6, 399-408, November 2000
© 2000 AlphaMed Press

Concise Review

Consequences of BCR-ABL Expression within the Hematopoietic Stem Cell in Chronic Myeloid Leukemia

Janusz H. S. Kabarowskia, Owen N. Wittea,b

a Department of Microbiology, Immunology, and Molecular Genetics, and
b Howard Hughes Medical Institute, University of California, Los Angeles, California, USA

Key Words. Chronic myeloid leukemia • BCR-ABL • Stem cells

Janusz Kabarowski, Ph.D., HHMI/UCLA, 5-748 MRL Bldg., 675 Charles E. Young Dr. S., Los Angeles, California 90095-1662, USA. Telephone: 310-825-0169; Fax: 310-206-8822; e-mail: januszk{at}microbio.ucla.edu

Chronic myeloid leukemia (CML) was the first human malignancy shown to be associated with a specific cytogenetic lesion, the Philadelphia chromosomal translocation. Forty years on, many biological and biochemical properties have been ascribed to its molecular product, the BCR-ABL tyrosine kinase fusion protein. However, it has been difficult to establish their precise contribution to the deregulation of normal survival, proliferative and differentiative control in chronic phase CML and the degree to which the involvement of stem cells extends beyond their role as the aetiological target. This review will focus on our current understanding of the pathogenesis of CML from the perspective of stem cell involvement, and how the biological and biochemical properties ascribed to BCR-ABL from studies of in vitro transformation and in vivo leukemogenesis systems relate to the abnormalities manifest in the human disease.




This article has been cited by other articles:


Home page
 BloodHome page
R. A. J. Signer, E. Montecino-Rodriguez, O. N. Witte, J. McLaughlin, and K. Dorshkind
Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia
Blood, September 15, 2007; 110(6): 1831 - 1839.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
R. Kuribara, H. Honda, H. Matsui, T. Shinjyo, T. Inukai, K. Sugita, S. Nakazawa, H. Hirai, K. Ozawa, and T. Inaba
Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors
Mol. Cell. Biol., July 15, 2004; 24(14): 6172 - 6183.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. A. McLean, I. Gathmann, R. Capdeville, M. H. Polymeropoulos, and M. Dressman
Pharmacogenomic Analysis of Cytogenetic Response in Chronic Myeloid Leukemia Patients Treated with Imatinib
Clin. Cancer Res., January 1, 2004; 10(1): 155 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Wong, J. McLaughlin, D. Cheng, K. Shannon, L. Robb, and O. N. Witte
IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease
PNAS, September 30, 2003; 100(20): 11630 - 11635.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. Asnafi, I. Radford-Weiss, N. Dastugue, C. Bayle, D. Leboeuf, C. Charrin, R. Garand, M. Lafage-Pochitaloff, E. Delabesse, A. Buzyn, et al.
CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCR{gamma}{delta} lineage
Blood, August 1, 2003; 102(3): 1000 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Wong, J. McLaughlin, D. Cheng, and O. N. Witte
Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors
Blood, May 15, 2003; 101(10): 4088 - 4097.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
A. Strife, D. Wisniewski, C. Liu, C. L. Lambek, Z. Darzynkiewicz, R. T. Silver, and B. Clarkson
Direct Evidence That Bcr-Abl Tyrosine Kinase Activity Disrupts Normal Synergistic Interactions Between Kit Ligand and Cytokines in Primary Primitive Progenitor Cells
Mol. Cancer Res., January 1, 2003; 1(3): 176 - 185.
[Abstract] [Full Text]

Home page
 J. Exp. Med.Home page
A. Ptasznik, E. Urbanowska, S. Chinta, M. A. Costa, B. A. Katz, M. A. Stanislaus, G. Demir, D. Linnekin, Z. K. Pan, and A. M. Gewirtz
Crosstalk Between BCR/ABL Oncoprotein and CXCR4 Signaling through a Src Family Kinase in Human Leukemia Cells
J. Exp. Med., September 2, 2002; 196(5): 667 - 678.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Wisniewski, C. L. Lambek, C. Liu, A. Strife, D. R. Veach, B. Nagar, M. A. Young, T. Schindler, W. G. Bornmann, J. R. Bertino, et al.
Characterization of Potent Inhibitors of the Bcr-Abl and the c-Kit Receptor Tyrosine Kinases
Cancer Res., August 1, 2002; 62(15): 4244 - 4255.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. C. Wolff and R. L. Ilaria Jr
Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571
Blood, November 1, 2001; 98(9): 2808 - 2816.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
H. Karlic, N. Louda, M. Pfeilstocker, F. Keil, A. Lohninger, E. Pittermann, and J. Paukovits
Effect of the Hemoregulatory Peptide (pEEDCK)2 (pyroGlu-Glu-Asp-Cys-Lys)2 and MIP-1{alpha} is Reduced in Bone Marrow Cultures from Patients with Chronic Myeloid Leukemia (CML)
Stem Cells, July 1, 2001; 19(4): 321 - 328.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
Email Content Delivery
Copyright © 2000 by AlphaMed Press.